Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Gilead Japan Revving Up Oncology Drive with Trodelvy, CAR-T as Legs of Growth
Gilead Sciences is boosting its oncology business in Japan, centering on its anti-TROP-2 antibody drug conjugate (ADC) Trodelvy (sacituzumab govitecan) launched last year as well as CAR-T cell therapies, also with an eye on a sales force expansion. The company’s…
To read the full story
Related Article
- Gilead’s Japan Revenue Up 15% in 2025 as Trodelvy Gains Traction
March 19, 2026
- Kite Looks to Expand Japan CAR-T Footprint, Boosts Supply Infrastructure
October 15, 2025
- Gilead Shelves Sunlenca’s PrEP Program in Japan as Coverage Issue Weighs
April 17, 2025
- Expert Hails Japan Approval of Gilead’s Trodelvy for Triple-Negative Breast Cancer
October 30, 2024
- Gilead Eager to See More Authorized CAR-T Treatment Centers in Japan
June 21, 2024
- Gilead Japan Ramping Up Sales Force with Trodelvy Now under Review
February 20, 2024
BUSINESS
- Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
- Takeda Hit with Massive Damages Verdict in US Amitiza Antitrust Case
May 20, 2026
- Top Generic Makers Grow Sales on Higher Output, Shipment Recovery
May 20, 2026
- Tapinarof Cream Logs Positive Data in Infant Atopic Dermatitis: Shionogi
May 20, 2026
- Bayer Files FXIa Inhibitor Asundexian in Japan
May 20, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…